Drugs Made In America Acquisition II Corp(DMII) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 15 at 4:10 PM ET (Korea 9/16 05:10)
Full metrics table
| Index | - | P/E | 49.95 | EPS (ttm) | 0.2 | Insider Own | 22.15% | Shs Outstand | 63.7M | Perf Week | 0.05% |
| Market Cap | 0.65B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 49.6M | Perf Month | 0.39% |
| Enterprise Value | 0.65B | PEG | - | EPS next Q | - | Inst Own | 71.1% | Short Float | 0.24% | Perf Quarter | 0.89% |
| Income | 0.01B | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 1.37 | Perf Half Y | 2.11% |
| Sales | 0.00B | P/B | 1.31 | EPS next 5Y | - | ROA | 5.06% | Short Interest | 0.12M | Perf YTD | 2.73% |
| Book/sh | 7.79 | P/C | 3810.78 | EPS past 3/5Y | - | ROE | 5.25% | 52W High | -0.39% ($10.21) | Perf Year | - |
| Cash/sh | 0 | P/FCF | - | Sales past 3/5Y | - | ROIC | 2.62% | 52W Low | 3.14% ($9.86) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 0.2% 0.15% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.02 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.34 | EPS Q/Q | 11600% | Profit Margin | - | RSI (14) | 61.62 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.34 | Sales Q/Q | - | SMA20 | 0.18% ($10.15) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | 0.53% ($10.12) | Rel Volume | 2.47 | Prev Close | $10.18 |
| Employees | 2 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 1.53% ($10.02) | Avg Volume(3M) | 0.09M | Price | $10.17 |
| IPO | 2025/12/3 | Option/Short | No/Yes | Trades | 134 | Volume | 215,135 | Change | -0.1% |
Company
DMII is a Financial sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
💊 Drugs Made in America Acquisition II (DMII) is a special purpose acquisition company (SPAC) launched with the pharmaceutical industry as its merger target. It operates under a blank-check structure, placing the funds raised through its IPO in a trust account while seeking a merger partner that is a pharmaceutical or biotech company with a proven business model.
Over the past 1 year, on the higher side
0% below its 1-year high.
DMII has weak earning power
Tap to view numbers
The price looks about right
Trading at 50.0 times earnings.
Tap to view numbers
Long-term returns are close to the market
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 71.1%.
Tap to view numbers
It ranks #3 in the industry
Based on market cap of $648M.
DMII $648M PER 50.0
LION $3B PER -
CCXI $671M PER -
EVAC $601M PER 35.8
FAQ
What kind of company is DMII?
DMII belongs to the Financial sector and operates in the Shell Companies industry.
What is the market cap of DMII?
The market cap of DMII is approximately $648M, ranking 2,992 within its sector.
What is the P/E ratio of DMII?
DMII has a P/E ratio of approximately 50.0x, which can be used to assess its valuation relative to the Financial sector average.
What is the 52-week high and low for DMII?
DMII has recorded a 52-week high of $10.21 and a low of $9.86.
